References
- Mitchell P, Liew G, Gopinath B, et al. Age-related macular degeneration. Lancet. 2018 Sep 29;392(10153):1147–1159. doi: 10.1016/S0140-6736(18)31550-2
- Loewenstein A, Trivizki O. Future perspectives for treating patients with geographic atrophy. Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1525–1531. doi: 10.1007/s00417-022-05931-z
- Yednock T, Fong DS, Lad EM. C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degeneration. Int J Retina Vitreous. 2022 Nov 8;8(1):79.
- Spaide RF, Vavvas DG. COMPLEMENT INHIBITION for GEOGRAPHIC ATROPHY: review of salient functional outcomes and perspective. Retina. 2023 Jul 1;43(7):1064–1069.
- Tzoumas N, Riding G, Williams MA, et al. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3
- FDA. US FDA Pegcet acoplan Approval. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217171Orig1s000ltr.pdf
- G R. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. ARVO 2022 IOVS. 2022. https://iovs.arvojournals.org/article.aspx?articleid=2779604
- Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmol. 2021 Apr;128(4):576–586. doi: 10.1016/j.ophtha.2020.08.027
- Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 Sep 8;402(10411):1449–1458. doi: 10.1016/S0140-6736(23)01583-0
- Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov. 2010 Jan;9(1):43–56. doi: 10.1038/nrd3011
- Sepp T, Khan JC, Thurlby DA, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci. 2006 Feb;47(2):536–540. doi: 10.1167/iovs.05-1143
- Zheng R, Zhang Y, Zhang K, et al. The complement system, aging, and aging-related diseases. Int J Mol Sci. 2022 Aug 4;23(15):8689. doi: 10.3390/ijms23158689
- Defendi F, Thielens NM, Clavarino G, et al. The immunopathology of complement proteins and innate immunity in autoimmune disease. Clin Rev Allergy Immunol. 2020 Apr;58(2):229–251. doi: 10.1007/s12016-019-08774-5
- Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol. 2007 Sep;44(16):3875–3888. doi: 10.1016/j.molimm.2007.06.005
- Kjaer TR, Thiel S, Andersen GR. Toward a structure-based comprehension of the lectin pathway of complement. Mol Immunol. 2013 Dec 15;56(3):222–231.
- Rooijakkers SH, Ruyken M, Roos A, et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol. 2005 Sep;6(9):920–927. doi: 10.1038/ni1235
- Zipfel PF, Heinen S, Jozsi M, et al. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol. 2006 Jan;43(1–2):97–106. doi: 10.1016/j.molimm.2005.06.015
- Doorduijn DJ, Lukassen MV, van ‘t Wout MFL, et al. Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5. Elife. 2022 Aug 10;11. doi: 10.7554/eLife.77503
- Fritsche LG, Chen W, Schu M, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013 Apr;45(4):433-9, 439e1–2.
- Sofat R, Casas JP, Webster AR, et al. Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol. 2012 Feb;41(1):250–262. doi: 10.1093/ije/dyr204
- Scholl HP, Fleckenstein M, Fritsche LG, et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One. 2009 Oct 12;4(10):e7418. doi: 10.1371/journal.pone.0007418
- Caire J, Recalde S, Velazquez-Villoria A, et al. Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration. JAMA Ophthalmol. 2014 May;132(5):528–534. doi: 10.1001/jamaophthalmol.2013.8175
- Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmol. 2018 Mar;125(3):369–390. doi: 10.1016/j.ophtha.2017.08.038
- Grassmann F, Fleckenstein M, Chew EY, et al. Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration. PLoS One. 2015;10(5):e0126636. doi: 10.1371/journal.pone.0126636
- Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001 Nov;20(6):705–732. doi: 10.1016/S1350-9462(01)00010-6
- Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy. Ophthalmol. 2021 Sep;128(9):1325–1336. doi: 10.1016/j.ophtha.2021.02.025
- Hoy SM. Pegcetacoplan: First Approval. Drugs. 2021 Aug;81(12):1423–1430. doi: 10.1007/s40265-021-01560-8
- Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmol. 2020 Feb;127(2):186–195. doi: 10.1016/j.ophtha.2019.07.011
- Patel SS, Lally DR, Hsu J, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 Mar 24; doi: 10.1038/s41433-023-02497-w
- 2023. https://www.prnewswire.com/news-releases/iveric-bio-receives-us-fda-approval-for-izervay-avacincaptad-pegol-intravitreal-solution-a-new-treatment-for-geographic-atrophy-301894042.html
- Iveric bio to present top-line results for avacincaptad pegol from phase 3 GATHER2 clinical trial in geographic atrophy at AAO 2022 annual meeting. 2023. https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-present-top-line-results-avacincaptad-pegol-phase-3
- Wykoff CC, Hershberger V, Eichenbaum D, et al. Inhibition of complement factor 3 in geographic atrophy with NGM621: phase 1 dose-escalation study results. Am J Ophthalmol. 2022 Mar;235:131–142.
- ngmbio. Results from phase II CATALINA trial. 2023. https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-presentation-post-hoc-analyses-catalina-phase/
- ANNEXON TOPLINE DATA FROM ARCHER PHASE 2 TRIAL OF ANX007 IN GEOGRAPHIC ATROPHY DEMONSTRATED STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT PRESERVATION OF VISUAL FUNCTION. 2023. https://ir.annexonbio.com/news-releases/news-release-details/annexon-topline-data-archer-phase-2-trial-anx007-geographic/
- Pastor JC, Rojas J, Pastor-Idoate S. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2016 Mar;51:125–155.
- ClinicalTrial.gov. GOLDEN STUDY: a study to assess safety and efficacy of multiple doses of IONIS-FB-LRx in participants with geographic atrophy secondary to age-related macular degeneration (AMD). 2023. https://www.clinicaltrials.gov/study/NCT03815825?intr=IONIS-FB-LRx%20&rank=2
- ClinicalTrial.gov. EXPLORE: a phase II study to evaluate the safety and efficacy of two doses of GT005 (EXPLORE). 2023. https://www.clinicaltrials.gov/study/NCT04437368?intr=GT005&rank=1
- ClinicalTrial.gov. HORIZON: a phase II study to evaluate the safety and efficacy of two doses of GT005. 2020. https://classic.clinicaltrials.gov/ct2/show/NCT04566445
- Janssen announces late-breaking data from two gene therapy programs at the American academy of ophthalmology 2022 annual meeting. 2022. https://www.jnj.com/janssen-announces-late-breaking-data-from-two-gene-therapy-programs-at-the-american-academy-of-ophthalmology-2022-annual-meeting
- ClinicalTrial.gov A study of Danicopan in participants with geographic atrophy secondary to age-related macular degeneration https://www.clinicaltrials.gov/study/NCT05019521?intr=ALXN2040&rank=2 2023
- ASRS. ASRS: Six Cases of Occlusive Retinal Vasculitis Reported After Injection of Apellis’ GA Drug Syfovre. 2023. https://eyewire.news/news/asrs-rare-cases-of-retinal-vasculitis-reported-after-injection-of-apellis-ga-drug-syfovre?c4src=article:infinite-scroll
- Richard AJ, Duker JS, Reichel E. Geographic atrophy: where we are now and where we are going. Curr Opin Ophthalmol. 2021 May 1;32(3):247–252.
- Bio I. Results from GATHER 2. 2023. https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-announces-new-functional-vision-loss-reduction-data
- Holz FG, Sadda SR, Busbee B. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018 Jun 1;136(6):666–677.
- Georgiannakis A, Burgoyne T, Lueck K. Retinal pigment epithelial cells mitigate the effects of complement attack by endocytosis of C5b-9. J Immunol. 2015 Oct 1;195(7):3382–3389.